Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874855 · ClinicalTrials.gov registry record · Phase 4
Lemborexant in Delayed Sleep Phase Syndrome
A Phase 4 study of Delayed Sleep Phase Syndrome, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06874855 is a Phase 4 study of Delayed Sleep Phase Syndrome that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06874855, a Phase 4 study of Delayed Sleep Phase Syndrome, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, the investigators will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lemborexant
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06874855
The ClinicalTrials.gov registry entry for NCT06874855 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delayed Sleep Phase Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06874855 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06874855 about?
NCT06874855 is a clinical study titled "Lemborexant in Delayed Sleep Phase Syndrome". The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, the investigators w...
What is the current status of trial NCT06874855?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2023-03-13. Estimated completion is 2027-05-31.
What conditions does trial NCT06874855 study?
This clinical trial studies the following conditions: Delayed Sleep Phase Syndrome.
What interventions are being tested in trial NCT06874855?
The interventions under investigation include: Placebo (DRUG), Lemborexant (DRUG).
Who is sponsoring clinical trial NCT06874855?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06874855 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Sleep Phase Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.